Message

From: Keigwin, Richard [Keigwin.Richard@epa.gov]
Sent: 2/15/2017 11:45:46 AM
To: MARVIN, THOMAS [AG/1920] [thomas.marvin@monsanto.com]
CC: Goodis, Michael [Goodis.Michael@epa.gov]
Subject: Re: Tioxazafen New Active Ingredient, FR Notice?

Tom--

Thanks for your note and welcome to your new position. I look forward to working with you.

I expect that, within the next few days, we will be poised to start the public participation process on the proposed decision for this new active ingredient. Once the upcoming public comment period concludes and after considering any comments that we may receive, I expect that we will be able to make a registration decision in relatively short order.

--Rick

Rick Keigwin
Acting Director, Office of Pesticide Programs
U.S. Environmental Protection Agency

Sent from my iPhone

On Feb 14, 2017, at 6:22 PM, MARVIN, THOMAS [AG/1920] <thomas.marvin@monsanto.com> wrote:

> Greetings Rick,
>
> First, congratulations on your appointment as Acting Office Director. I look forward to working with you in the capacity of my new role—leading the regulatory team at Monsanto's DC office. Second, I am requesting your assistance to understand the status of our new active ingredient nematicide, Tioxazafen, that is pending EPA's publication in the FR and the start of a public comment period. We understood that EPA was prepared to initiate that action in early January, 2017, but that the "Regulatory Freeze" caused a delay. As each day passes, our commercial timelines are increasingly jeopardized. We are desperately looking for some indication of the current status and timing of EPA's FR publication. Please let me know if there is anything we can do to help explain the urgency, and thank you in advance for any information you can provide.
>
> Tom
>
> Tom Marvin
> Director, Federal Regulatory Affairs
> Monsanto Co.
> 1300 I Street, NW
> Washington, DC 20005
> Cell: 314-308-6836
> Desk: 314-694-7901